Datapoint: FDA Approves Bristol Myers Squibb’s Breyanzi
After a series of regulatory and manufacturing delays, the FDA last week approved Bristol Myers Squibb’s CAR-T drug Breyanzi for the treatment of large B-cell lymphoma in patients who have not responded to or relapsed following other systemic treatments. Two other CAR-T therapies, Novartis’s Kymriah and Gilead’s Yescarta, are approved for the treatment of large B-cell lymphoma. Under the pharmacy benefit, Kymriah and Yescarta both hold preferred status for 9% of all covered lives.
SOURCE: MMIT Analytics, as of 2/8/21